Imagion Biosystems Ltd. (AU:IBX) has released an update.
Imagion Biosystems Ltd. has amended terms in its convertible securities agreement with Mercer Street Global Opportunity Fund, significantly lowering the floor price for conversions and adjusting the maturity dates for notes. The company also settled an event of default by issuing shares to Mercer and announced a cleansing offer to facilitate unrestricted trading of these new shares. Imagion focuses on developing medical imaging technologies and is progressing in clinical development of its MagSense® platform for cancer diagnosis.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.
